Calidi Biotherapeutics Reports Narrowed Q1 2025 Net Loss and Advances in Cancer Immunotherapy

Calidi Biotherapeutics (NYSE American: CLDI) has announced a net loss of $5.0 million for the first quarter of 2025, a notable improvement from the $7.2 million loss reported in the same period the previous year. This financial update comes alongside significant advancements in the company's research and development efforts, particularly in the field of cancer immunotherapy. The reduction in net loss was attributed to decreased research and development (R&D) and general and administrative (G&A) expenses, reflecting the company's strategic focus on optimizing its operations.

Among the key developments, Calidi Biotherapeutics received FDA clearance for its Investigational New Drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy targeting solid tumors. This milestone underscores the potential of CLD-201 to address unmet needs in oncology, offering hope for patients with challenging-to-treat cancers. Additionally, the company presented promising data from its Redtail platform at the American Association for Cancer Research (AACR) meeting. The data showcased the platform's ability to deliver an IL15 superagonist via an engineered oncolytic virus, highlighting a novel approach to enhancing the immune system's ability to fight cancer.

Calidi Biotherapeutics also strengthened its leadership team with the appointment of Dr. Eric Poma as CEO and Dr. Guy Clifton as Chief Medical Officer. These additions are expected to bolster the company's efforts in advancing systemic virotherapies for metastatic cancers. The company's focus on developing proprietary technologies that leverage the immune system to combat cancer positions it as a key player in the biotechnology sector. For more details on Calidi Biotherapeutics' recent achievements and financial performance, visit https://ibn.fm/mqF2M.